Search Results

Revascularization for patients with ischaemic left ventricular (LV) systolic dysfunction takes one of two forms - percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG), both of which have positives and negatives. STICH, published in 2011, analysed the role of CABG in patients with LV systolic dysfunction and looked at improvement of clinical outcomes in 1,212 patients from 22 countries across the world, optimised to either optimal medical therapy or optimal medical therapy plus CABG. REVIVED-BCIS2 in 2022 looked at 700 patients in the UK with a similar patient population of 35% ejection fraction or less, randomized to PCI or optimal medical therapy. This interview dives into their analysis of the results from these exciting trials and investigation into the discrepancies between the outcomes.

The Ground-BrEAking Electroporation-based inTervention for Atrial Fibrillation (BEAT-AF) treatment project is an initiative funded by the European Commission from the European Union’s Horizon 2020 research and innovation programme, and managed under the European Health and Digital Executive Agency (grant number 945125).1,2 The study was also partly funded by IHU LIRYC ANR-10-IAHU-04. This pioneering 5-year programme commenced on […]

Highlights The autonomic nervous system plays a critical role in the aetiopathogenesis of atrial fibrillation (AF). Neuromodulation of the autonomic nervous system has been a topic of increased interest in the management of AF. Ablation of ganglionated plexi, ethanol ablation of the vein of Marshall, renal denervation and pulmonary vein isolation have demonstrated promising results […]

Infiltrative cardiomyopathies are a diverse group of cardiac diseases caused by the deposition of abnormal substances within the myocardium and include diseases, such as Fabry disease, sarcoidosis and less common genetic diseases, such as Friedreich’s ataxia and Danon disease.1 Cardiac amyloidosis is the exemplar infiltrative cardiomyopathy and is characterized by the deposition of misfolded precursor proteins into […]

Catheter ablation (CA) is an invasive adjunctive therapeutic option for atrial and ventricular arrhythmias, in uncontrolled cases, following optimal medical therapy.1,2 The validation of 3D mapping and its implementation into clinical usage has been a remarkable achievement in the field of complex ablation of scar-related ventricular tachycardia (VT) in the early 2000s.3 In the setting of atrial […]

The third European Pacing Symposium (EPS) meeting took place on Friday 1 December 2023 in London, UK. The event, which brings together an international faculty to discuss the latest advances in cardiac pacing and implantable cardioverter-defibrillators (ICDs) provides attendees with practical sessions and examines some of the most recent findings and techniques in the field. […]

Clinically relevant tricuspid regurgitation (TR) is a common disorder, affecting approximately 4% of people 75 years of age or older.1 If left untreated, severe TR results in volume overload and right ventricular remodelling. This eventually leads to symptomatic right-sided heart failure, along with increased morbidity and mortality. This disease is highly undertreated due to high complication […]

Welcome to the latest issue of the European Journal of Arrhythmia & Electrophysiology, the official journal of the Arrhythmia Alliance. We are honoured to present a series of compelling articles that reflect cutting-edge developments and diverse perspectives in this ever-evolving field. Richard Ang opens the edition with the first in a series of expert interviews […]